Likewise, setting adequate compensation, as required under TRIPS Article 31(h) has never been predictable or easily administered.[15] Additionally, and of similar importance, other questions remain outstanding, including which countries qualify for parallel imports,[16] navigating the complexities of licensing agreements,[17] ensuring timeliness during public health emergencies,[18] and achieving cooperation from pharmaceutical companies who arguably have little incentive to cooperate.[19]… [read post]